Interní Med. 2003; 5(3): 102-108

Vztah cholesterolu k metabolickému syndromu

prof. MUDr. Štěpán Svačina DrSc
III. interní klinika VFN a 1. LF UK, Praha

Keywords: HDL-cholesterol, weight reduction, insulin resistance, oxidised LDL particles, plant sterols, hypolipidemic drugs.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Vztah cholesterolu k metabolickému syndromu. Interní Med. 2003;5(3):102-108.

Hyperliproteinémie provázející metabolický syndrom je charakterizována třemi fenomény: zvýšenou triglyceridémií, sníženým HDL cholesterolem a přítomností tzv. malých denzních oxidovaných LDL částic. Přestože celkový cholesterol není zvýšen, jde o výrazně aterogenní kombinaci. Nízká hladina HDL cholesterolu a hypertriglyceridémie přitom patří k tzv. jádru metabolického syndromu a má velmi pevnou vazbu na inzulinorezistenci. V léčbě rizikových nemocných vyjádřenými více složkami metabolického syndromu musí být využity všechny nefarmakologické i farmakologické postupy k normalizaci hladiny triglyceridů, HDL cholesterolu i LDL cholesterolu.

Relation of cholesterol level to metabolic syndrome

Dyslipidemia of metabolic syndrome is characterised by 3 phenomena: high triacylglycerol level, low level of HDL-cholesterol and presence of small dense oxidized LDL-particles. Although the level of total choplesterol is not increased, this dyslipidemia is very atrherogenic. Low level of HDL-cholesterol and hypertriacylglycerolemia is a part of so called core of metabolic syndrom with a strong relation to insulin resistance. It is necessary to use all non-pharmacological and pharmacological approaches to normalise the level of triacylglycerols, HDL-cholesterol and LDL-cholesterol in these high risk patients.

Download citation

References

  1. Barrett PH, Watts GF. Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr Opin Lipidol 2003; 14: 61-68. Go to original source... Go to PubMed...
  2. Dixon JB, O´Brian PE. Lipid profile in the Severaly obese. Obesity research 2002; 10: 903-909. Go to original source... Go to PubMed...
  3. European Group for the study of insulin resistance: Frequency of the WHO metabolic syndrome in european cohorts. Diabetes Metab 2002; 28: 364-376.
  4. Expert Panel. Clinical guidelines on the identification, evaluation and tretament of owerweight in adults: Executive summary. Am J Clin Nutr 1998; 68: 899-917. Go to original source... Go to PubMed...
  5. Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002; 39: 209-213. Go to original source... Go to PubMed...
  6. Gustat J, et al. Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. J Clin Epidemiol 2002; 55: 997-1006. Go to original source... Go to PubMed...
  7. Kahleova R, et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857-864. Go to original source... Go to PubMed...
  8. Macut D, et al. Age and body mass related changes of cardiovascular risk factors in women with polycystic ovary syndrome. Vojnosanit Pregl 2002; 59: 593-599. Go to original source... Go to PubMed...
  9. Melenovsky V, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002; 144: E6. Go to original source... Go to PubMed...
  10. Mokdad AH, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79. Go to original source... Go to PubMed...
  11. Moreau RA, Whitaker BD, Hicks KB. Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health-promoting uses. Prog Lipid Res 2002; 41: 457-500. Go to original source... Go to PubMed...
  12. Murtaugh MA, et al. Relation of birth weight to fasting insulin, insulin resistance, and body size in adolescence. Diabetes Care 2003; 26: 187-192. Go to original source... Go to PubMed...
  13. Paragh G, et al. Disturbed regulation of cholesterol synthesis in monocytes of obese patients with hypercholesterolemia. Metabolism 2003; 52: 1-6. Go to original source... Go to PubMed...
  14. Park KW, et al. The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Koreans. Clin Genet 2003; 63: 31-38. Go to original source... Go to PubMed...
  15. Raikkonen K, et al. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002; 51: 1573-1577. Go to original source... Go to PubMed...
  16. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500. Go to original source... Go to PubMed...
  17. Simonen P, et al. Introducing a new component of the metabolic syndrome: low cholesterol absorption American Journal of Clinical Nutrition 2000; 72: 82-88. Go to original source... Go to PubMed...
  18. Svačina Š. Obezita a psychofarmaka. Praha: Triton 2002; 180 s.
  19. Svačina Š, Owen K. Syndrom inzulinové rezistence Praha: Triton 2003, 250 s.
  20. Visoulis GP, et al. Differentiation of betabloker effects on serum lipids and apolipoproteins in hypertenive patients Europ Heart J, 1992; 13: 1506-1513. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.